Name:	akca_AllocableArrangementConsideration
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to delivery of the active pharmaceutical ingredient (API) for the drug under the collaboration agreement.

No definition available.

Name:	akca_ConsiderationAllocatedToDeliveryOfActivePharmaceuticalIngredient
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to development activities for the drug under the collaboration agreement.

No definition available.

Name:	akca_ConsiderationAllocatedToDevelopmentActivities
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The number of agreements with the collaboration partner, including collaboration and other types of agreements.

No definition available.

Name:	akca_NumberOfAgreements
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of categories of milestone events used in collaboration agreements to determine milestone payments.

No definition available.

Name:	akca_NumberOfCategoriesOfMilestoneEvents
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of drugs with an exclusive option that could be exercised to develop and commercialize the drug and a license fee is paid under the collaboration agreement. The collaboration partner will assume all further global development, regulatory and commercialization activities for the licensed drug.

No definition available.

Name:	akca_NumberOfDrugsWithExclusiveOptionThatCouldBeExercised
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of stages in the life-cycle of drugs.

No definition available.

Name:	akca_NumberOfStagesInLifeCycleOfDrugs
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The period of time after inception of the collaboration agreement for an initial public offering (IPO) to be completed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodFromInceptionOfAgreementForIPOToBeCompleted
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete Investigational New Drug (IND)-enabling animal studies for a new development candidate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodToCompleteINDEnablingAnimalStudies
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete a Phase 1 clinical trial, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodToCompletePhase1ClinicalTrial
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete a Phase 2 clinical trial, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodToCompletePhase2ClinicalTrial
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete a Phase 3 clinical trial, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodToCompletePhase3ClinicalTrial
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to obtain marketing authorization from the applicable regulatory agency after an application is submitted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodToObtainMarketingAuthorizationFromApplicableRegulatoryAgency
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to prepare and submit regulatory filngs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	akca_PeriodToPrepareAndSubmitRegulatoryFilings
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of a pre-specified sales threshold that can be used to trigger a commercialization milestone payment under the collaboration agreement.

No definition available.

Name:	akca_PreSpecifiedProductSalesThresholdIncludedInCommercializationMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The premium received if an initial public offering (IPO) is not completed within 15 months after inception of the collaboration agreement.

No definition available.

Name:	akca_PremiumReceivedIfIPOIsNotCompletedAfterInceptionOfAgreement
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The total amount of the premium received over the trading price of common stock at the time of purchase.

No definition available.

Name:	akca_PremiumReceivedOnSharesIssued
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the number of separate units of accounting requiring the allocation of consideration for revenue recognition purposes under the multi-deliverable arrangement.

No definition available.

Name:	akca_RevenueRecognitionMultiDeliverableArrangementNumberOfUnitsOfAccounting
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The amount of upfront payments received during the period under the collaboration agreement.

No definition available.

Name:	akca_UpfrontPaymentReceived
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The cash inflow from the additional capital contribution to the entity.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

Name:	us-gaap_RevenueRecognitionAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Number of new stock issued during the period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=akca_StrategicCollaborationAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_ProductOrServiceAxis=akca_AKCEAAPOALMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_ProductOrServiceAxis=akca_AKCEAAPOCIIILMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=akca_StockPurchaseAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: